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Abstract
Background: Acetylsalicylic acid (ASA) is one of the basic drugs used in the secondary prevention of 
coronary artery disease (CAD), and in most cases it is taken in the morning in one daily dose. It is sug-
gested that the morning peak of platelet aggregation is responsible for the occurrence of myocardial in-
farctions and strokes. Hence, the aim of the study was to observe the effect of ASA (morning vs. evening) 
dosing on the anti-aggregative effect of platelets in patients with CAD and arterial hypertension (AH). 
Methods: The study involved 175 patients with CAD and AH. Patients were randomly assigned to 
one of two study groups, taking ASA in the morning or in the evening. The patients had two visits, one 
baseline and another after 3 months from changing the time of ASA dosage. The platelet aggregation 
was determined using the VerifyNow analyzer.
Results: In the ASA evening group, a significant reduction in platelet aggregation was obtained. In 
the ASA morning group, a significant difference in response to ASA was observed, depending on sex. In 
men, the reactivity of platelets decreased, but in women it increased. 
Conclusions: In the group of patients with CAD and AH, bedtime ASA dosing is associated with  
a significant reduction in platelet aggregation. The response to ASA may differ between sexes. The ben-
efit gained by changing the drug administration from the morning to the evening is greater in women. 
(Cardiol J 2019; 26, 6: 727–735)
Key words: acetylsalicylic acid, platelet aggregation, bedtime administration,  
chronotherapy, circadian rhythm, gender-dependence, randomized controlled trial
Introduction
The functioning of the human body is sub-
jected to cyclical variability in the form of oscilla-
tion of physiological phenomena called biological 
rhythms [1]. These include circadian rhythms that 
can significantly affect the function of the cardio-
vascular system [2]. It is suggested that changes 
in circadian rhythms in the coagulation system are 
one of the causes of sudden deaths, myocardial 
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infarctions (MI), and ischemic strokes that occur 
more often when switching from the sleep phase 
to the awakening [2]. It has been shown that during 
the morning there is an increase in blood pressure, 
episodes of sudden cardiac death, unstable angina, 
and rupture of the aortic dissecting aneurysm are 
more frequent [3–6]. In the Framingham, ISAM, 
and TIMI II studies the incidence of MI was 3-fold 
higher in the morning than in the late evening 
[7–9]. A registry of 45,000 patients showed a higher 
incidence of ST-segment elevation MI heart attacks 
in the morning (41%) compared to the afternoon 
and night hours (respectively, 32% and 26%, p < 
< 0.001) [10]. The mechanisms of these phenome-
na are not fully understood; it is suggested that one 
of the reasons may be a morning increase in blood 
viscosity due to platelet hyperaggregation and de-
creased fibrinolytic activity, leading to an increased 
risk of thromboembolic events [11–14]. There-
fore, it would be useful to use the chronotherapy 
principles in acetylsalicylic acid (ASA) therapy 
to reduce the incidence of acute cardiovascular 
events that occur in the morning. Chronotherapy 
involves adjusting the concentration and potency 
of the drug over time in accordance with biologi-
cal circadian rhythms [15, 16]. To date, few papers 
about the influence of taking ASA on the morning 
peak of platelet activity have been published. ASA 
belongs to the basic drugs used in the secondary 
prevention of coronary artery disease (CAD), and 
in most cases it is taken in one daily dose in the 
morning hours [17, 18]. The epidemiological data 
and clinical observations described above prompted 
interest in changing the dose of ASA from a morning 
dose to bedtime. The aim of the present study was 
to observe the effect of ASA (morning vs. evening) 
dosing on the antiaggregative effect of platelets in 
a high-risk group of cardiovascular patients.
Methods
The study included 200 patients, aged 59.8 
years, with diagnosed CAD and arterial hyperten-
sion (AH), who were taking ASA 75 mg/day in 
a single antiplatelet therapy, and who were admitted 
to the Department of Hypertension. Eventually 
the inclusion criteria were met by 175 patients 
(59 women and 116 men). The recruitment pe-
riod was 21 months (from May 2015 to January 
2017). Patients with CAD and AH were randomly 
assigned to one of two study groups taking ASA 
in the morning (58 patients) or in the evening (56 
patients). The third group, which was the control, 
included 61 patients with AH, without CAD, and 
not taking any antiplatelet drugs (Table 1). The 
study was approved by the Bioethics Committee 
of Karol Marcinkowski University of Medical Sci-
ences in Poznan (Resolution No. 373/15). Each 
participant signed informed consent to participate 
in the study, which was a form approved by the 
Bioethical Committee. Exclusion criteria for the 
study were as follows: secondary hypertension, 
MI and stroke within 6 months prior to the study, 
chronic heart failure — New York Heart Asso-
ciation (NYHA) III and IV, chronic kidney disease 
(glomerular filtration rate < 30 mL/min), addiction 
to alcohol or psychotropic substances, and active 
cancer. Additional exclusion criteria for the study 
group were: confirmed hypersensitivity to ASA, 
history of bleeding due to ASA, taking clopidogrel 
or other antiplatelet agents, hemorrhagic diathesis, 
active gastric and/or duodenal ulcer disease, and 
hypersensitivity to an active substance: ASA, other 
salicylates or any component of the drug, using 
non-steroidal anti-inflammatory drugs (NSAID). 
The exclusion criterion for the control group was 
the use of ASA preparations in the preceding 
30 days. There were no changes in the concomitant 
treatment (lipid-lowering, antihypertensive, and 
antidiabetic), and no NSAID were taken during 
the study.
Scheme of the study
Patients enrolled in the study had two visits in 
accordance with a prescribed treatment schedule 
(Fig. 1). On the first qualifying visit (Visit 1), the 
patients were admitted to the ward where labora-
tory and imaging examinations with the assess-
ment of the severity of platelet aggregation using 
the VerifyNow Aspirin Test and randomization 
regarding the inclusion of ASA morning or evening 
took place. After 3 months of ASA therapy, Visit 2 
was administered, during which the examinations 
from the initial visit were repeated. 
VerifyNow Aspirin Test
During a single whole blood sample collection, 
2.2 mL vacuum collection tubes with 3.2% sodium 
citrate were used, together with 21-gauge needles 
as recommended by the manufacturer.
VerifyNow Aspirin assay contains lyophilised 
fibrinogen-coated beads and a platelet agonist — 
arachidonic acid. It is designed to measure platelet 
function based on the ability of activated platelets 
to bind fibrinogen. Fibrinogen-coated microparti-
cles aggregate in whole blood in proportion to the 
number of unblocked platelet glycoprotein (GP) 
IIb/IIIa receptors. Light transmittance increases 
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as activated platelets bind and aggregate fibrino-
gen-coated beads. The instrument measures this 
change in the optical signal caused by aggregation. 
Assay results are reported as Aspirin Reaction 
Units (ARU), which are calculated as a function of 
the rate of aggregation. ARU values < 550 indicate 
an effective result of ASA, while ARU values > 550 
indicate no effect of the drug.
Statistical analysis
Statistical analyses were performed with 
Statistica, version 12.5 (StatSoft, USA). Since the 
tested data had not met the assumption of Gaussian 
distribution (evaluated with Shapiro-Wilk method), 
non-parametric methods were applied. The Krus-
kal-Wallis ANOVA test was used for evaluation of 
the differences in parameters between the three 
Table 1. Patient demographic characteristics 
Acetylsalicylic acid Control group  
(n = 61)
P
Morning (n = 58) Evening (n = 56)
Female/male 19/39 19/37 21/40 > 0.05*
Smokers/non-smokers 14/44 17/39 17/44 > 0.05*
Age [years] 59.8 ± 7.6 60.3 ± 7.1 59.9 ± 7.1 > 0.05**
Weight [kg] 84.4 ± 9.7 84.9 ± 12.9 84.1 ± 10.1 > 0.05**
Height [m] 1.69 ± 0.1 1.69 ± 0.1 1.69 ± 0.1 > 0.05**
BMI [kg/m2] 29.52 ± 3.95 29.50 ± 4.4 29.52 ± 4.1 > 0.05**
Waist [cm] 93.1 ± 11.1 92.5 ± 11.4 93.7 ± 11.6 > 0.05**
Hip [cm] 105.2 ± 10.2 105.3 ± 12.3 105.2 ± 10.6 > 0.05**
Waist to hip ratio 0.88 ± 0.05 0.87 ± 0.06 0.89 ± 0.08 > 0.05**
Systolic BP [mmHg] 145.5 ± 5.0 145.2 ± 6.7 145.1 ± 5.2 > 0.05**
Diastolic BP [mmHg] 88.8 ± 4.0 88.8 ± 5.3 89.0 ± 5.5 > 0.05**
Data are shown as number or mean ± standard deviation. Statistics: *Chi-square; **Kruskal-Wallis ANOVA; BMI — body mass index; BP — 
blood pressure
Patients with coronary heart disease and artherial hypertension
Recrutation and qualication (n = 200)
Randomization
Group 1 (n = 58)
CAD and AH
ASA morning
Group 2 (n = 56)
CAD and AH
ASA evening
Group 3 (n = 61)
AH
without ASA
Without ASA3 months therapy ASA morning versus evening
Laboratory and imaging examination* clinical BP, VerifyNow Aspirin Test
Laboratory tests, clinical BP, VerifyNow Aspirin Test
Visit 1
Visit 2
Figure 1. Scheme of the study. *In each group: Laboratory tests, abdominal ultrasound examination, abdominal com-
puted tomography scan, Doppler ultrasound of renal arteries, clinical blood pressure (3×/24 h), electrocardiography, 
echocardiography, weight, and body mass index assessment; AH — arterial hypertension; ASA — acetylsalicylic acid; 
BP — blood pressure; CAD — coronary artery disease
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groups. Changes in parameters in the individual 
groups during the first and second visit were ana-
lyzed using the Wilcoxon signed-rank test — the 
parametric equivalent of the T-test for related 
variables. Frequencies, expressed on a nominal 
scale, were analyzed based on the Pearson c2 test. 
A p-value < 0.05 was considered significant.
Results 
Table 1 presents the basic clinical and de-
mographic data of the group of patients studied. 
Selected parameters: body mass index (BMI), 
weight, waist, hips did not change significantly in 
any of the studied groups or in the control group, be-
tween groups and between Visits 1 and 2 (p > 0.05, 
Wilcoxon signed-rank test). Table 2 presents the 
data from the interviewed population, includ-
ing concomitant diseases. Table 3 summarizes 
the most important drugs (antihypertensive, hy-
polipemic and antidiabetic) taken by the patients. 
What is important, is that there was no significant 
difference between the groups in the amount of the 
drugs administered during the therapy and there 
was no change of drugs during the study. In all 
patients, a qualitative measurement of platelet ag-
gregation was also performed using the VerifyNow 
Aspirin Test. Figure 2 presents the results of the 
examination of inhibition of platelet aggregation in 
individual groups during the first and second visit.
The result of the Aspirin VerifyNow Test was 
given as the severity of platelet aggregation in 
ARU. At the baseline visit, the inhibition of aggre-
gation in ARUs did not differ between the groups 
and was 489.01 ± 73.0 in the morning ASA group 
and 488.16 ± 83.0 in the evening ASA group. In 
the control group, which did not take ASA, the 
result was 638.31 ± 15.9 ARU. Only in the ASA 
evening group, a significant reduction in platelet 
aggregation of 28 ARUs was obtained compared 
to the morning ASA group (460.10 ± 82.3 h vs. 
487.62 ± 77.4 h in the morning; p < 0.05).
Figure 3 shows changes in ARU on Visit 2, de-
pending on sex (p-value applies to Mann-Whitney 
U test), compared to Visit 1. In the group that 
took ASA in the morning, a significant difference 
in response to ASA was observed, depending on 
sex. In men, the reactivity of platelets decreased 
by 9.5 ± 44.3 ARU, and in women, conversely, it 
increased by 13.9 ± 48.2 ARU. The size of this 
decline in the ASA group in the morning in men 
was lower than in the ASA group in the even-
ing. There was no correlation between age, BMI 
waist to hip ratio of the patients, and change in 
Table 2. Patient clinical data of the groups.  
Acetylsalicylic acid Control 
group
Morning Evening
Coronary heart  
disease
58 56 0
Arterial hypertension 58 56 61
Diabetes mellitus 15 17 14 
Metabolic syndrome 21 20 22 
History of myocardial 
infarction 
12 13 0
Previous ischemic 
stroke or transient  
cerebral ischemia 
5 6 0
History of coronary  
artery bypass surgery 
8 9 0
History of coronary 
angioplasty 
38 37 0
Hyperlipidemia 58 56 61
Atherosclerosis of  
the lower limbs 
7 6 5
Chronic obstructive 
pulmonary disease 
6 7 5
Thyroid disease 4 5 6
Table 3. Drugs used in groups studied.
Acetylsalicylic acid Control 
group
Morning Evening
Acetylsalicylic acid 58a 56a 0b
Anti-hypertensive 
drugs 
2.58a 2.66a 2.57a 
b-blockers 58a 56a 53a
Angiotensin-converting 
enzyme inhibitors 
40a 34a 40a
Angiotensin II receptor 
antagonists 
18a 22a 21a
Calcium antagonists 22a 25 25
Diuretics/aldosterone 
antagonists 
13a 12 16a
Concomitant lipid-
lowering therapy 
58a 56a 58a
Concomitant  
antidiabetic therapy  
(metformin) 
15a 17a 14a
Proton pump inhibitors 47a 45a 42a
a, bDifferent letters given in the upper index indicate the occurrence 
of statistical differences in the values of a given parameter between 
the three groups (Kruskal-Wallis ANOVA, p < 0.05)
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platelet aggregation after the change of dosage 
to bedtime. The changes in laboratory tests were 
also noted. Only in the ASA evening group was 
there a decrease in the number of platelets and an 
increase in uric acid concentration. There were no 
changes in other laboratory parameters between 
groups (Table 4).
Discussion 
On the basis of data from epidemiological 
studies, it has been shown that circadian rhythms 
can affect both the physiology and pathology in the 
cardiovascular system [19, 20]. In the early morn-
ing hours, a higher incidence of MIs, sudden cardiac 
death, ventricular malignant arrhythmia, stroke, and 
acute aortic dissection is observed [21–24]. MIs, 
which occur between 6 a.m. and 12 noon, cause 
21% more damage to the myocardium, which is 
a factor that worsens prognosis [19, 25]. Aggregation 
of platelets and the level of aggregation markers 
have their circadian rhythm peaking between 6 a.m. 
and 12 noon [26, 27]. The severity of platelet ag-
gregation in the morning may be associated with an 
increase in the number of acute coronary syndromes 
[28]. It seems that it is important to look for new 
ways to properly inhibit platelet aggregation in the 
morning. One of these methods could be an evening 
administration of ASA. The aim of the study was to 
compare the effect of ASA on platelet aggregation, 
depending on the time of drug administration in 
the morning versus in the evening, in patients with 
CAD and first- and second-degree AH, according to 
European Society of Hypertension (ESH)/European 
Society of Cardiology (ESC) 2013 [29–31]. 
In the current observation, in the evening 
ASA group, a significant reduction in platelet ag-
gregation of 28 ARU was obtained compared to the 
morning ASA group (460.10 ± 82.3 h vs. 487.62 ± 
± 77.4 h in the morning; p < 0.05). At the base-
line visit, the results of inhibition of aggregation 
in ARUs did not differ between the groups and 
were 489.01 ± 73.0 in the morning ASA group and 
488.16 ± 83.0 in the evening ASA group. This is in 
line with the results obtained by Bonten et al. [32]. 
In their study of 290 patients with normal blood 
pressure or mild AH, they showed that ASA given 
in the evening reduced platelet reactivity by an 
average of 22 ARU compared to the morning ASA 
group [32]. In another study, in a small group of 
healthy volunteers, the same researchers marked 
cyclooxygenase-1 (COX-1)-dependent platelet ac-
tivity (using the VerifyNow Aspirin Test) and the 
level of thromboxane B2 (STxB2). They showed 
reduced platelet activity of 23 ARU platelet in 
VerifyNow Aspirin Test and a reduction in TXB2 
by 1.7 ng/mL in those who took ASA at bedtime 
compared to those who took ASA in the morning. 
This confirms the effect of a low-dose ASA taken 
at bedtime on the reduction of COX-1-dependent 
platelet activity in healthy people [25, 33].
Acetylsalicylic acid is rapidly and almost com-
pletely absorbed in the stomach and duodenum by 
passive diffusion. Due to the short half-life, which 
is 2–3 h, ASA inhibits about 90% of platelets that 
are present in the plasma when the drug is taken. 
Figure 2. Change in Aspirin Reaction Units (ARU) be-
tween Visit 1 and 2 in groups studied (p-value refers 
to Wilcoxon-signed rank test); ASA — acetylsalicylic 
acid.
Figure 3. Change in Aspirin Reaction Units (ARU) at Visit 
2 in relation to Visit 1 in the groups studied in relation 
to patient sex (p-value refers to Mann-Whitney U test); 
ASA — acetylsalicylic acid.
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Table 4. Laboratory tests of the groups studied at Visit 1 and Visit 2.
Acetylsalicylic acid Control group
Morning Evening
Hemoglobin [mmol/L] Visit 1 8.8 ± 0.74a 8.7 ± 0.58a 8.9 ± 0.73a
Visit 2 8.8 ± 0.7a 8.6 ± 0.7a 8.9 ± 0.7a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
Platelets [10–9/L] Visit 1 225.7 ± 54.3a 227.6 ± 56.9a 224.5 ± 61.1a
Visit 2 226.9 ± 36.8a 197.9 ± 41.5b 226.0 ± 60.2a
P (Wilcoxon) > 0.05 < 0.05 > 0.05
Na [mmol/L] Visit 1 141.2 ± 2.5a 141.1 ± 2.2a 141.7 ± 2.1a
Visit 2 141.0 ± 2.1a 140.9 ± 2.2a 141.9 ± 2.3a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
K [mmol/L] Visit 1 4.3 ± 0.45a 4.3 ± 0.4a 4.2 ± 0.4a
Visit 2 4.3 ± 0.3a 4.3 ± 0.4a, b 4.2 ± 0.3b
P (Wilcoxon) > 0.05 > 0.05 > 0.05
Total cholesterol [mmol/L] Visit 1 4.8 ± 1.1a 4.7 ± 1.0a 4.7 ± 0.9a
Visit 2 4.7 ± 0.9 a 4.8 ± 1.1a 4.4 ± 0.9a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
LDL-C [mmol/L] Visit 1 1.3 ± 0.4a 1.4 ± 0.5a 1.4 ± 0.5a
Visit 2 1.5 ± 0.5a 1.5 ± 0.6a 1.7 ± 0.6a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
HDL-C [mmol/L] Visit 1 2.6 ± 1.0a 2.5 ± 0.9a 2.5 ± 0.7a
Visit 2 2.5 ± 0.8a 2.4 ± 0.8a 2.5 ± 0.7a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
Triglicerydes [mmol/L] Visit 1 1.6 ± 0.5a 1.6 ± 0.4a 1.5 ± 0.8a
Visit 2 1.6 ± 0.4a 1.5 ± 0.5a 1.7 ± 0.8a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
GFR [mL/min/1.73 m2] Visit 1 80.4 ± 9.7a 79.3 ± 12.6a 78.8 ± 11.7a
Visit 2 80.6 ± 9.0a 82.9 ± 8.9a 79.7 ± 9.9a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
Serum creatinine [µmol/L] Visit 1 82.2 ± 5.1a 82.2 ± 5.1a 81.6 ± 5.2a
Visit 2 79.4 ± 15.4a 82.9 ± 12.0a 82.3 ± 10.9a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
Glucose [mmol/L] Visit 1 5.2 ± 0.9a 5.2 ± 0.7a 5.2 ± 0.6a
Visit 2 5.1 ± 0.7a 5.3 ± 0.7a 5.1 ± 0.5a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
Urid acid [umol/l] Visit 1 331.9 ± 101a 334.3 ± 99a 330.7 ± 97a
Visit 2 332.7 ± 105a 379.1 ± 71b 328.9 ± 99a
P (Wilcoxon) > 0.05 < 0.05 > 0.05
CRP [mg/L] Visit 1 2.0 ± 1.8a 1.9 ± 0.9a 1.9 ± 0.8a
Visit 2 2.1 ± 1.6a 2.1 ± 1.0a 1.8 ± 0.8a
P (Wilcoxon) > 0.05 > 0.05 > 0.05
a, bDifferent letters given in the upper index indicate the occurrence of statistical differences in the values of a given parameter between the 
three groups (Kruskal-Wallis ANOVA, p < 0.05); CRP — C-reactive protein; GFR — glomerular filtration rate; HDL-C — high density lipoprotein 
cholesterol; LDL-C — low density lipoprotein cholesterol
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It should be remembered that physiologically, at all 
the times, new and uninhibited plates are released 
into the blood, which constitute about 10% of the 
total number. The release of new platelets may be 
greater in people with vascular disease [34–36]. It 
has been shown that in up to 25% of patients, inhibi-
tion of platelets by ASA decreases gradually within 
24 h after its administration [18, 37]. In his work, 
Kirszbacher et al. [38] confirmed that the time of 
taking ASA can affect the incidence of cardiovas-
cular events and can change the effectiveness of 
prophylaxis. If the drug is given in the morning, it 
was obvious that the highest plasma drug levels 
occurred after the morning peak of the incidence of 
a thromboembolic event. Moreover, the method of 
morning ASA administration has a lower protective 
value for the prevention of cardiovascular events 
at night and early in the morning, when the lack 
of physical activity further promotes platelet ag-
gregation and ischemia. In contrast, the highest 
plasma concentration of ASA administered late 
in the evening reaches its maximum before the 
peak of thromboembolic events [38–40]. Henry et 
al. [41] evaluated the biological effect of low-dose 
ASA in 150 patients with CAD. Platelet aggrega-
tion increased gradually after taking the drug in the 
second hour after only 4.7% and after 12 h in 11% 
of patients, respectively. These results correlated 
with elevated levels of inflammatory markers, 
smoking, and diabetes. The authors suggested 
that administration of ASA once per 24 h (regard-
less of dose, 75 mg or > 100 mg) does not provide 
stable 24-h antiplatelet protection in a significant 
proportion of patients with CAD [41]. Studies by 
other authors have clearly demonstrated that the 
antiplatelet effect of ASA decreases within 24 
h after a single administration of the drug. The 
observation referred to 100 patients with diabe-
tes and 73 non-diabetic patients. In both groups, 
the production of thromboxane (TXA2) was sig-
nificantly inhibited after 12 h and was followed by 
a slow recovery of platelet activity. Greater body 
weight was the only independent predictor of faster 
return of COX-1 activity, but only in non-diabetic 
subjects. It has been shown that dosing ASA once 
a day may cause COX-1 activity to return more rap-
idly and may result in incomplete TAX2 inhibition. 
In contrast, 100 mg ASA taken twice a day caused 
complete TAX2 blocking in both groups. The authors 
concluded that insufficient inhibition of TAX2 can be 
easily corrected by changing the diagram from once 
a day to twice a day [37]. This mechanism, due to 
limitations and assumptions of this paper, has not 
been analyzed. 
The findings of the present study are in line 
with previously conducted trials by Bonten et al. 
[32, 33], and they confirm that bedtime ASA in-
take has a better effect on decreasing the platelet 
reactivity than an intake on awakening. However, 
the present study also demonstrated the signifi-
cant gender-dependence difference in response 
to ASA administrated in the morning. In men, the 
reactivity of platelets decreased by 9.5 ± 44.3 
ARU, whereas in women it increased by 13.9 ± 
± 48.2 ARU. In men, the size of this decline in the 
ASA morning group was lower than in the ASA 
evening group. It is known that the antiplatelet 
effect of ASA gradually decreases within 24 h after 
administration [41]. In this study, platelet activ-
ity during Visit 2 was measured in the morning, 
which is 12 h and 24 h after taking ASA, in the 
group receiving the drug in the evening and in 
the morning, respectively. The striking difference 
between men and women in the latter group is 
probably due to the overall higher platelet reactiv-
ity in women [42]. Therefore COX-1 dependent 
platelet inhibition may be shorter than in men. 
Therefore, morning intake of ASA in women is 
not only ineffective in response to platelets, but 
it can also cause an adverse response, which is 
particularly important in patients with a high risk 
of cardiovascular disease. This fact could be an 
additional argument to dose ASA in the evening 
because its activity is then independent of sex. 
However, this requires further observation.
Conclusions
1. In the group of patients with ischemic heart 
disease and hypertension, dosing ASA at 
bedtime compared to dosing the morning is as-
sociated with a significant reduction in platelet 
aggregation, which is determined using the 
VerifyNow analyzer. 
2. The response to ASA in patients with ischemic 
heart disease and hypertension may differ 
from one sex to another. The research sug-
gests that the benefit gained by changing the 
drug administration from the morning to the 
evening is greater in women.
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